Multiple Sclerosis

With some patients being treated for multiple sclerosis with Aubagio for more than a decade questions have been raised about the safety of the treatment for such a long period of time. Further research has shown it to still be safe for the people who need it most.

It can be easy to look at the treatment of multiple sclerosis and stop at the physical symptoms of the disease. For patients living with the condition their daily lives are about more than the symptoms and making them work within their own individual challenges.

Magnetic resonance imaging (MRI) can be used to identify lesions in the central nervous system in patients with multiple sclerosis (MS), but not all patients with active disease have identifiable lesions, and researchers are mixed over the extent to which lesions can be used as a marker for MS disease activity.

Delayed-release dimethyl fumarate (DMF, also known as gastro-resistant DMF) is effective at lowering disease activity long-term in patients with relapsing-remitting multiple sclerosis (RRMS), according to Eva Havrdova, MD, of Charles University of Prague. The findings are set to be presented in a poster session at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain.

When it comes to treating and studying multiple sclerosis, the correlation between magnetic resonance imaging (MRI) lesions and actual disease activity has been widely disputed. A new analysis says that using MRI lesions as a proxy for disease activity is a sufficient approach when determining primary endpoints in clinical trials.

The results from an on-going phase 4 trial add to the growing evidence that teriflunomide is effective for relapsing-remitting multiple sclerosis, according to Patricia K. Coyle, MD, of Stony Brook University in New York.

Better understanding the relationship between inflammation and biomarkers could help improve treatments for those with multiple sclerosis.

Participation in daily life activities is primarily hindered by reduced processing speed in patients with multiple sclerosis.

Delayed-release dimethyl fumarate (DMF) proved to be safe and effective in two phase 3 studies, DEFINE and CONFIRM, for patients with relapsing-remitting multiple sclerosis (RRMS). Gavin Giovannoni, MBBCh, PhD, FRCP, FRCPath, of the Queen Mary University of London and colleagues took a more detailed look to verify the data.

Alemtuzumab is an effective strategy to prevent relapses and other disease activity associated with multiple sclerosis (MS), according to Heinz Wiendl, MD, a professor at the University of Münster. The research will be explained in a poster session at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain.

Race and vitamin D levels may play a crucial role in the risk of multiple sclerosis (MS), according to Annette M. Langer-Gould, MD, PhD, of Kaiser Permanente in Pasadena, California. The findings are set to be presented in a poster session at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain.

Ann Romney, wife of 2012 Republican Presidential Nominee Mitt Romney, released her memoir discussing her marriage, her diagnosis with multiple sclerosis (MS), her faith, and other inspirational stories of overcoming adversity

A Clinical and Experimental Rheumatology review offers a critical analysis of recent studies on systemic sclerosis to best classify and manage this chronic condition.

Primary fatigue associated with multiple sclerosis (MS) is generally considered to be related to centrally mediated processes of the disease, while secondary fatigue is believed to be a result of the host of factors that can accompany MS, such as depression or sleep disturbance.

Last night's Republican primary debate provided further evidence that many people still believe that autism is caused by vaccines.

California's "End of Life Option Act" faces stiff opposition from the American College of Physicians. The bill will become state law unless California's Gov. Jerry Brown vetoes it.

Exercising may reduce disease activity for pediatric patients with multiple sclerosis, according to the results of a study published in Neurology.

This article summarizes the most popular diet plans in MS for easier use in your clinical practice.

High-sodium diets could be a risk factor for multiple sclerosis (MS) in addition to genetic predisposition and additional factors, according to research published in The FASEB Journal.

Patients with multiple sclerosis experience decreased connectivity between brain regions leading to the cognitive changes that are a trademark of the disease, according to research published in Neuropsychology.

A nanometric sensor may be able to identify biomarkers of pathological conditions such as multiple sclerosis (MS), neuromyelitis optica, and certain types of cancer, according to research published in Sensors Journal.

Patients with multiple sclerosis may have an increased risk of earlier death, a study in Neurology found.

Autoimmune diseases like multiple sclerosis are more common in women, though mice models may clue researchers into the reasoning behind the phenomena.

The Food and Drug Administration (FDA) has issued a warning regarding a serious side effect associated with a drug used to treat multiple sclerosis (MS).

Balance issues for multiple sclerosis patients may be caused by T cells malfunctioning, according to findings published in Immunity.

Patients diagnosed with systemic sclerosis (SSc) may have a three times greater risk of venous thromboembolism (VTE) – including potentially deadly clots in the lungs – and an increased risk in the first year after a diagnosis.

Researchers have identified a gene that is associated with treatment success in patients with multiple sclerosis being treated with interferon-beta.

Medication costs for multiple sclerosis have grown at an "alarming" rate over the past 20 years, according to research published in Neurology.

Pain is prevalent in 63% of patients with multiple sclerosis (MS), according to a recent study, and psychosocial factors may be key contributors to the severity of that pain.

GM CFS may be an effective novel therapy for multiple sclerosis.